After insurance for New York City employees began covering GLP-1 weight-loss injectables, more than 1,000 city workers and ...

News and talk of GLP-1 drugs are everywhere these days—from their smash success in treating Type 2 diabetes and obesity to ...

As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim ...

Study of patients who started taking blockbuster weight loss drugs in 2021 suggests patients need support services, not just ...

A new study by researchers at Brigham and Women's Hospital in collaboration with researchers at Harvard T.H. Chan School of ...

The findings spell an uncertain future for hospitals and clinics that derive a significant portion of their revenues from ...

Ozempic and other GLP-1 drugs show promise not only in managing obesity and diabetes but also in reducing Alzheimer's risk. A ...

The demand for bariatric operations dropped sharply last year as use of anti-obesity drugs such as Wegovy surged, study finds ...

Researchers from Mass General Brigham and collaborators found that use of GLP-1 drugs to treat obesity more than doubled from 2022 to 2023 while rates ...

As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim ...

Companies are figuring out how to cater to consumers using GLP-1 drugs, such as Ozempic.

Moving ahead, Rob Rowe, Regional Research Director and Head of Global Strategy at a large US bank is ‘ tactically bullish ’ on the back of continuing tech recovery and the markets “pricing in a soft ...